☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

MTRAC update glitazone advice

The Midlands Therapeutics Review and Advisory Committee (MTRAC) has issued updated advice for pioglitazone (Actos®) and rosiglitazone (Avandia®).

The pioglitazone review places this drug as having weaker evidence and having a lower place in therapy. It is suitable for restricted prescribing in primary care because of conflicting evidence in the long-term clinical effects of this drug on cardiovascular outcomes.

The rosiglitazone review recommends that this drug should not be prescribed in primary care because of "inadequate evidence of safety and/or efficacy".

Action: Current recommendations still stand. Metformin continues to be the first choice oral hypoglycaemic with a sulphonylurea added in as second line. This is based upon a proven record of efficacy and safety.

Share 'MTRAC update glitazone advice' by emailShare 'MTRAC update glitazone advice' on FacebookShare 'MTRAC update glitazone advice' on TwitterShare 'MTRAC update glitazone advice' on LinkedInShare 'MTRAC update glitazone advice' on reddit


No Comments to “MTRAC update glitazone advice”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.